Resumen de acción BCRX * BioCryst Pharmaceuticals, Inc, empresa de biotecnología, desarrolla terapias orales de moléculas pequeñas y proteínas para tratar enfermedades raras. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de BioCryst Pharmaceuticals, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del BioCryst Pharmaceuticals Precios históricos de las acciones Precio actual de la acción US$155.00 Máximo en las últimas 52 semanas US$170.00 Mínimo de 52 semanas US$98.29 Beta 1.77 Cambio en 1 mes 0% Variación en 3 meses n/a Cambio de 1 año n/a Variación en 3 años -39.22% Variación en 5 años n/a Variación desde la OPV 127.77%
Noticias y actualizaciones recientes
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
Insufficient new directors Nov 12
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05
BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat) Oct 14
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome Oct 02 Ver más actualizaciones
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
Insufficient new directors Nov 12
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05
BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat) Oct 14
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome Oct 02
BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat) Sep 17
Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer Sep 05
BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 Aug 05
BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 22
BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO May 15
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO May 10
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 May 09
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 May 08
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 23
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency Apr 17
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 Feb 29
Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022) Feb 27
Forecast to breakeven in 2026 Feb 23
BioCryst Launches Orladeyo (Berotralstat) in Italy Feb 20
BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 13
Forecast to breakeven in 2026 Jan 12
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 Jan 06
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat) Dec 19
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023 Dec 01
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina Nov 29
BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO Nov 22
BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat) Nov 11
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023 Nov 03
BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology Oct 28
Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013 Oct 27
BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec Sep 19
Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022) Aug 04
BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Biocryst Pharmaceuticals, Inc. Announces Executive Changes Jul 12
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile May 23
BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 08
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema Jan 27
BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases Jan 10
High number of new directors Dec 07
BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health Nov 29
High number of new directors Nov 16
Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy Nov 11
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022 Nov 02
BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
High number of new directors Oct 03
BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer Sep 15
FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva Sep 01
Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients Aug 27
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia Aug 19
BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program Aug 06
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021) Aug 05
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 05
High number of new directors Aug 04
BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) Jul 02
BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 Jun 23
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 10
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 09
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic Jun 08
Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks Jun 07
High number of new directors May 30
First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 1Q 2021) May 06
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022 May 06
European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva Apr 28
High number of new directors Apr 27
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022 Apr 26
BioCryst Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
BioCryst Pharmaceuticals, Inc. Pauses Enrollment in BCX9930 Clinical Trials Apr 09
High number of new directors Apr 08
Biocryst Pharmaceuticals, Inc. Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among Hae Patients Following Long-Term Treatment with Orladeyo Feb 25 BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022
BioCryst Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 10
BioCryst Appoints Machelle Sanders to Board of Directors Feb 09
High number of new directors Jan 29
BioCryst Pharmaceuticals, Inc. Provides ORLADEYO Net Revenue and Peak Sales Guidance for Full Year 2022 Jan 12
BioCryst Pharmaceuticals, Inc. Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Jan 09
BioCryst Pharmaceuticals, Inc Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Dec 01
Director recently bought Mex$2.0m worth of stock Nov 26
High number of new directors Nov 22
Independent Director recently sold Mex$899k worth of stock Sep 15
High number of new directors Sep 15
High number of new directors Sep 07
BioCryst Pharmaceuticals, Inc. Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic Aug 26
Senior VP & Chief Business Officer Megan Sniecinski has left the company Aug 14
Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.24 loss in 2Q 2020) Aug 06
Director Vincent Milano has joined 3rd company board Aug 03
Director Vincent Milano has joined 3rd company board Aug 03
Director Vincent Milano has joined 3rd company board Aug 03
BioCryst Pharmaceuticals, Inc. Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH Jul 16 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Microcap Growth Index
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO™ (berotralstat) in Germany Jun 04
Independent Director recently sold Mex$1.8m worth of stock May 14
Forecast to breakeven in 2024 May 14 Rentabilidad de los accionistas BCRX * MX Biotechs Mercado MX 7D 0% 0% 0% 1Y n/a 0% 0%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Datos insuficientes para calcular los resultados de BCRX * en comparación con la industria MX Biotechs.
Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de BCRX * frente al mercado MX.
Volatilidad de los precios Is BCRX *'s price volatile compared to industry and market? BCRX * volatility BCRX * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Precio estable de las acciones: El precio de las acciones de BCRX * ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de BCRX * en el último año.
Acerca de la empresa BioCryst Pharmaceuticals, Inc, empresa de biotecnología, desarrolla terapias orales de moléculas pequeñas y proteínas para tratar enfermedades raras. La empresa comercializa peramivir inyectable, un inhibidor intravenoso de la neuraminidasa para el tratamiento de la gripe aguda no complicada bajo los nombres RAPIVAB, RAPIACTA y PERAMIFLU; y ORLADEYO, un inhibidor oral de la serina proteasa para tratar el angioedema hereditario. También está desarrollando BCX10013, un inhibidor oral del factor D para enfermedades mediadas por el complemento.
Mostrar más Resumen de fundamentos de BioCryst Pharmaceuticals, Inc. ¿Cómo se comparan los beneficios e ingresos de BioCryst Pharmaceuticals con su capitalización de mercado? Estadísticas fundamentales de BCRX * Capitalización bursátil Mex$32.04b Beneficios(TTM ) -Mex$2.50b Ingresos (TTM ) Mex$8.32b
3.9x Ratio precio-ventas (PS)
-12.8x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de BCRX * Ingresos US$412.58m Coste de los ingresos US$197.47m Beneficio bruto US$215.11m Otros gastos US$338.93m Beneficios -US$123.82m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.60 Margen bruto 52.14% Margen de beneficio neto -30.01% Ratio deuda/patrimonio -176.9%
¿Cómo se ha desempeñado BCRX * a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/26 23:04 Precio de las acciones al final del día 2024/11/11 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas BioCryst Pharmaceuticals, Inc. está cubierta por 30 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Huidong Wang Barclays Tazeen Ahmad BofA Global Research Dae Gon Ha BTIG
Mostrar 27 más analistas 
